title: [Clinical significance of mutant p53 protein expression in lung adenocarcinoma].
abstract: BACKGROUND
  P53 is a tumor protein that acts as a tumor suppressor. The mutation of P53 may cause loss of tumor suppressor functions and gain of functions favoring cellular proliferation and apoptosis inhibition. The clinical implications of the tumor protein P53 gene (TP53) mutation in lung adenocarcinoma are indefinite. The aim of this study is to explore the clinical significance of the mutant P53 protein expression in lung adenocarcinoma tissues.
  
  
  METHODS
  The clinicopathological data of 120 lung adenocarcinoma patients who underwent surgery were retrospectively analyzed. The mutant P53 protein expression was detected using the immunohistochemical method. Furthermore, the relationship between the mutant P53 expression and the clinicopathological parameters was analyzed using the Chi-square test, whereas that between the mutant P53 expression and overall survival was estimated using the Kaplan-Meier method and Cox regression model.
  
  
  RESULTS
  The mutant P53 protein expression rate was 63.3%. Accordingly, the mutant P53 expression was significantly associated with tumor size (P=0.041) and clinicopathological stage (P=0.025). On the one hand, a univariate survival analysis showed that tumor size (P=0.031), lymph node metastasis (P<0.001), clinicopathological stage (P<0.001), and mutant P53 expression (P=0.038) were associated with overall survival. On the other hand, a multivariate survival analysis showed that lymph node metastasis (P=0.014) was an independent poor prognostic factor for overall survival.
  
  
  CONCLUSIONS
  Patients with lung adenocarcinoma with mutant TP53 had a poor outcome. Accordingly, the mutant P53 protein may serve as a molecular prognosis marker for lung adenocarcinoma patients.
authors.affiliation: Department of Thoracic Surgery, Jiangsu Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Nanjing 210009, China;Nanjing Jiangbei People's Hospital, Nanjing 210048, China.
authors.forename: Chun'an
authors.initials: C
authors.lastname: Bian
authors.affiliation: Department of Thoracic Surgery, Jiangsu Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Nanjing 210009, China.
authors.forename: Zhongyou
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Thoracic Surgery, Jiangsu Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Nanjing 210009, China.
authors.forename: Youtao
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Thoracic Surgery, Jiangsu Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Nanjing 210009, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Thoracic Surgery, Jiangsu Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Nanjing 210009, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Xu
authors.affiliation: Public Health College of Nanjing Medical University, Nanjing 210029, China.
authors.forename: Hongbing
authors.initials: H
authors.lastname: Shen
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D016159:Tumor Suppressor Protein p53